SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage...
Ausführliche Beschreibung
Autor*in: |
Rueda Domínguez, A. [verfasserIn] Alfaro Lizaso, J. [verfasserIn] de la Cruz Merino, L. [verfasserIn] Gumá i Padró, J. [verfasserIn] Quero Blanco, C. [verfasserIn] Gómez Codina, J. [verfasserIn] Llanos Muñoz, M. [verfasserIn] Martinez Banaclocha, N. [verfasserIn] Rodriguez Abreu, D. [verfasserIn] Provencio Pulla, M. [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2015 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Revista de oncología - Barcelona : Doyma, 2000, 17(2015), 12 vom: 26. Okt., Seite 1005-1013 |
---|---|
Übergeordnetes Werk: |
volume:17 ; year:2015 ; number:12 ; day:26 ; month:10 ; pages:1005-1013 |
Links: |
---|
DOI / URN: |
10.1007/s12094-015-1429-1 |
---|
Katalog-ID: |
SPR024262714 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR024262714 | ||
003 | DE-627 | ||
005 | 20230519164623.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201006s2015 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12094-015-1429-1 |2 doi | |
035 | |a (DE-627)SPR024262714 | ||
035 | |a (SPR)s12094-015-1429-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Rueda Domínguez, A. |e verfasserin |4 aut | |
245 | 1 | 0 | |a SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
264 | 1 | |c 2015 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. | ||
650 | 4 | |a Oncohematology malignancies |7 (dpeaa)DE-He213 | |
650 | 4 | |a Hodgkin lymphoma |7 (dpeaa)DE-He213 | |
650 | 4 | |a Hodgkin lymphoma therapy |7 (dpeaa)DE-He213 | |
700 | 1 | |a Alfaro Lizaso, J. |e verfasserin |4 aut | |
700 | 1 | |a de la Cruz Merino, L. |e verfasserin |4 aut | |
700 | 1 | |a Gumá i Padró, J. |e verfasserin |4 aut | |
700 | 1 | |a Quero Blanco, C. |e verfasserin |4 aut | |
700 | 1 | |a Gómez Codina, J. |e verfasserin |4 aut | |
700 | 1 | |a Llanos Muñoz, M. |e verfasserin |4 aut | |
700 | 1 | |a Martinez Banaclocha, N. |e verfasserin |4 aut | |
700 | 1 | |a Rodriguez Abreu, D. |e verfasserin |4 aut | |
700 | 1 | |a Provencio Pulla, M. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Revista de oncología |d Barcelona : Doyma, 2000 |g 17(2015), 12 vom: 26. Okt., Seite 1005-1013 |w (DE-627)385985452 |w (DE-600)2143451-7 |x 1578-195X |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2015 |g number:12 |g day:26 |g month:10 |g pages:1005-1013 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12094-015-1429-1 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
951 | |a AR | ||
952 | |d 17 |j 2015 |e 12 |b 26 |c 10 |h 1005-1013 |
author_variant |
d a r da dar l j a lj lja l c m l d lcml lcmld i p j g ipj ipjg b c q bc bcq c j g cj cjg m m l mm mml b n m bn bnm a d r ad adr p m p pm pmp |
---|---|
matchkey_str |
article:1578195X:2015----::emlncludlnsoteramno |
hierarchy_sort_str |
2015 |
publishDate |
2015 |
allfields |
10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013 |
spelling |
10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013 |
allfields_unstemmed |
10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013 |
allfieldsGer |
10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013 |
allfieldsSound |
10.1007/s12094-015-1429-1 doi (DE-627)SPR024262714 (SPR)s12094-015-1429-1-e DE-627 ger DE-627 rakwb eng 610 ASE Rueda Domínguez, A. verfasserin aut SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 Alfaro Lizaso, J. verfasserin aut de la Cruz Merino, L. verfasserin aut Gumá i Padró, J. verfasserin aut Quero Blanco, C. verfasserin aut Gómez Codina, J. verfasserin aut Llanos Muñoz, M. verfasserin aut Martinez Banaclocha, N. verfasserin aut Rodriguez Abreu, D. verfasserin aut Provencio Pulla, M. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 17(2015), 12 vom: 26. Okt., Seite 1005-1013 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 https://dx.doi.org/10.1007/s12094-015-1429-1 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 17 2015 12 26 10 1005-1013 |
language |
English |
source |
Enthalten in Revista de oncología 17(2015), 12 vom: 26. Okt., Seite 1005-1013 volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 |
sourceStr |
Enthalten in Revista de oncología 17(2015), 12 vom: 26. Okt., Seite 1005-1013 volume:17 year:2015 number:12 day:26 month:10 pages:1005-1013 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Oncohematology malignancies Hodgkin lymphoma Hodgkin lymphoma therapy |
dewey-raw |
610 |
isfreeaccess_bool |
true |
container_title |
Revista de oncología |
authorswithroles_txt_mv |
Rueda Domínguez, A. @@aut@@ Alfaro Lizaso, J. @@aut@@ de la Cruz Merino, L. @@aut@@ Gumá i Padró, J. @@aut@@ Quero Blanco, C. @@aut@@ Gómez Codina, J. @@aut@@ Llanos Muñoz, M. @@aut@@ Martinez Banaclocha, N. @@aut@@ Rodriguez Abreu, D. @@aut@@ Provencio Pulla, M. @@aut@@ |
publishDateDaySort_date |
2015-10-26T00:00:00Z |
hierarchy_top_id |
385985452 |
dewey-sort |
3610 |
id |
SPR024262714 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024262714</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164623.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-015-1429-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024262714</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-015-1429-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rueda Domínguez, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncohematology malignancies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hodgkin lymphoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hodgkin lymphoma therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alfaro Lizaso, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de la Cruz Merino, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gumá i Padró, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quero Blanco, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gómez Codina, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Llanos Muñoz, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martinez Banaclocha, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodriguez Abreu, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Provencio Pulla, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">17(2015), 12 vom: 26. Okt., Seite 1005-1013</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:12</subfield><subfield code="g">day:26</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:1005-1013</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-015-1429-1</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2015</subfield><subfield code="e">12</subfield><subfield code="b">26</subfield><subfield code="c">10</subfield><subfield code="h">1005-1013</subfield></datafield></record></collection>
|
author |
Rueda Domínguez, A. |
spellingShingle |
Rueda Domínguez, A. ddc 610 misc Oncohematology malignancies misc Hodgkin lymphoma misc Hodgkin lymphoma therapy SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
authorStr |
Rueda Domínguez, A. |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)385985452 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1578-195X |
topic_title |
610 ASE SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma Oncohematology malignancies (dpeaa)DE-He213 Hodgkin lymphoma (dpeaa)DE-He213 Hodgkin lymphoma therapy (dpeaa)DE-He213 |
topic |
ddc 610 misc Oncohematology malignancies misc Hodgkin lymphoma misc Hodgkin lymphoma therapy |
topic_unstemmed |
ddc 610 misc Oncohematology malignancies misc Hodgkin lymphoma misc Hodgkin lymphoma therapy |
topic_browse |
ddc 610 misc Oncohematology malignancies misc Hodgkin lymphoma misc Hodgkin lymphoma therapy |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Revista de oncología |
hierarchy_parent_id |
385985452 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Revista de oncología |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)385985452 (DE-600)2143451-7 |
title |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
ctrlnum |
(DE-627)SPR024262714 (SPR)s12094-015-1429-1-e |
title_full |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
author_sort |
Rueda Domínguez, A. |
journal |
Revista de oncología |
journalStr |
Revista de oncología |
lang_code |
eng |
isOA_bool |
true |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2015 |
contenttype_str_mv |
txt |
container_start_page |
1005 |
author_browse |
Rueda Domínguez, A. Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. |
container_volume |
17 |
class |
610 ASE |
format_se |
Elektronische Aufsätze |
author-letter |
Rueda Domínguez, A. |
doi_str_mv |
10.1007/s12094-015-1429-1 |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
seom clinical guidelines for the treatment of hodgkin’s lymphoma |
title_auth |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
abstract |
Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. |
abstractGer |
Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. |
abstract_unstemmed |
Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 |
container_issue |
12 |
title_short |
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma |
url |
https://dx.doi.org/10.1007/s12094-015-1429-1 |
remote_bool |
true |
author2 |
Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. |
author2Str |
Alfaro Lizaso, J. de la Cruz Merino, L. Gumá i Padró, J. Quero Blanco, C. Gómez Codina, J. Llanos Muñoz, M. Martinez Banaclocha, N. Rodriguez Abreu, D. Provencio Pulla, M. |
ppnlink |
385985452 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1007/s12094-015-1429-1 |
up_date |
2024-07-04T00:12:50.865Z |
_version_ |
1803605215405932544 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024262714</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164623.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-015-1429-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024262714</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-015-1429-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rueda Domínguez, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncohematology malignancies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hodgkin lymphoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hodgkin lymphoma therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alfaro Lizaso, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de la Cruz Merino, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gumá i Padró, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quero Blanco, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gómez Codina, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Llanos Muñoz, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martinez Banaclocha, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodriguez Abreu, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Provencio Pulla, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">17(2015), 12 vom: 26. Okt., Seite 1005-1013</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:12</subfield><subfield code="g">day:26</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:1005-1013</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-015-1429-1</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2015</subfield><subfield code="e">12</subfield><subfield code="b">26</subfield><subfield code="c">10</subfield><subfield code="h">1005-1013</subfield></datafield></record></collection>
|
score |
7.4006386 |